Abstract
Pemigatinib is a selective FGFR inhibitor that showed highly effectiveness and tolerability in patients with cholangiocarcinoma, which has been demonstrated in Fight 202 study with an ORR of 35.5%. However, pemigatinib has not been investigated in Chinese population with cholangiocarcinoma(CCA).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
